CEMI-LUNGNCT05363319
An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe
StatusActive, Not Recruiting
PhaseNot specified
SponsorRegeneron Pharmaceuticals
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 28 versions: 26 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Enrollment closed, study ongoing
- Trial sites reduced: 49 → 46 locations
- Enrollment target: estimated 500 to confirmed 509
- Primary and study completion dates: Oct 30, 2028 to Oct 3, 2028
- Notable Eligibility criteria expanded, about 10 words
- Secondary endpoints: details revised at 1 of 9 entries
- Site details revised at 1 of 49 sites
- Minor Site details revised at 2 of 49 sitesv25
- Minor Site details revised at 2 of 49 sitesv24
- Minor Site details revised at 1 of 49 sitesv23
Show 20 earlier versionsHide 20 earlier versions
- Minor Site details revised at 2 of 49 sitesv22
- Minor Site details revised at 4 of 49 sitesv21
- Minor Study sites: 48 to 49v20
- Minor Study sites revised (48)v19
- Minor Study sites: 45 to 48v18
- Minor Study sites: 26 to 45v17
- Minor Study sites: 23 to 26v16
Notable Enrollment target: 300 to 500v15 Show 9 more changesShow less
- Eligibility criteria shortened, about 45 words
- Primary endpoint revised
- Primary and study completion dates: Oct 27, 2028 to Oct 30, 2028
- Start date: Oct 27, 2022 to Oct 26, 2022
- Interventions: Cemiplimab (Drug) to Cemiplimab (Drug), Platinum-based chemotherapy (Drug)
- Secondary endpoints: 7 to 9
- Study description revised
- Study arms: 1 to 2
- Study title expanded, about 1 word
- Minor Site details revised at 3 of 23 sitesv14
- Minor Study sites: 22 to 23v13
- Notable Lead sponsor: Sanofi to Regeneron Pharmaceuticals
- Secondary endpoints revised (7)
- Study description expanded, about 10 words
- Collaborators shortened, about 2 words
- Minor Study sites: 20 to 22v11
- Minor Study sites: 18 to 20v10
- Minor Study sites: 10 to 18v9
- Minor Study sites: 9 to 10v8
- Minor Study sites: 7 to 9v7
- Minor Study sites: 6 to 7v6
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 6
- Primary and study completion dates: Sep 19, 2028 to Oct 27, 2028
- Start date changed from estimate of Sep 1, 2022 to Oct 27, 2022
- Notable Start date: Jul 6, 2022 to Sep 1, 2022
- Primary and study completion dates: Jun 6, 2028 to Sep 19, 2028
- Notable Start date: Jun 6, 2022 to Jul 6, 2022v3
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Overall survival (OS)
Timeframe: Up to 72 months
Secondary (9)
Overall Response Rate (ORR)
Duration of Response (DoR)
Time to Response (TTR)
Progression-Free Survival (PFS)
Time to first subsequent anti-NSCLC treatment (TTST)
Show 4 moreShow less
Incidence of treatment-related adverse events (TR-AEs) in patients with advanced NSCLC treated with a cemiplimab-based regimen in routine clinical practice
Incidence of treatment-related serious adverse events (TR-SAEs) in patients with advanced NSCLC treated with a cemiplimab-based regimen in routine clinical practice
Incidence and severity of immune-mediated adverse events (imAEs) in patients with advanced NSCLC treated with a cemiplimab-based regimen in routine clinical practice
Incidence and severity of infusion related reactions (IRRs) in patients with advanced NSCLC treated with a cemiplimab-based regimen in routine clinical practice
Arms and interventions
Cohort 1
Cemiplimab monotherapy
Cohort 2
Cemiplimab in combination with platinum-based chemotherapy
Drugs: Cemiplimab, Platinum-based chemotherapy
Sites
46 sites in 5 countries
Italy 13, Germany 11, Spain 11, France 9, Austria 2